Phaseline

Targets › RPLP0

RPLP0 (Large ribosomal subunit protein uL10): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 1 Phase 2, 1 Phase 4; Infectious disease; next expected readout May 2027.

Ribosomal protein P0 is the functional equivalent of E.coli protein L10. (UniProt, P05388)

Open in Phaseline: the race on RPLP0, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Marco SchiumaLinezolid
Bacterial 70S ribosome inhibitor
RPLP0Phase 4LinezolidOct 2027
Global Alliance for TB Drug Developmentlinezolid
Bacterial 70S ribosome inhibitor
RPLP0Phase 2Tuberculosis, PulmonaryMay 2027

Conditions

Tuberculosis, Pulmonary (1) Linezolid (1)

Modalities

small molecule (2)

Companies

Global Alliance for TB Drug Development (1) Marco Schiuma (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.